This is a paid press release. Contact the press release distributor directly with any inquiries.

Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs

Research and Markets

Thu, February 19, 2026 at 12:49 AM GMT+9 4 min read

Company Logo

Checkpoint inhibitors present significant market opportunities in oncology by enhancing immune responses to cancers like melanoma and lung cancer. Key prospects include emerging therapies targeting novel immune checkpoints, collaborations enhancing drug development, and first-in-class treatments promising improved patient outcomes.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) – The “Checkpoint Inhibitors - Competitive Landscape, 2026” has been added to ** ResearchAndMarkets.com’s** offering.

The report delivers extensive insights into over 50 companies and 60 drugs within the checkpoint inhibitors space. This comprehensive analysis highlights therapeutics assessment by product type, stage, route of administration, and molecule type, alongside a focus on inactive pipeline products.

Geographical Coverage: Global

Immune checkpoint inhibitors play a pivotal role in cancer treatment by enhancing the immune system’s ability to target cancer cells. These inhibitors work by blocking checkpoint proteins like CTLA-4, PD-1, and PD-L1, which can prevent T cells from attacking cancer cells. The report covers inhibitors such as CTLA-4, which enhances immune responses, PD-1 inhibitors preventing immune suppression, and PD-L1 inhibitors helping the immune system recognize cancer.

Checkpoint inhibitors enhance the immune response against various cancers such as melanoma, lung cancer, and kidney cancer. However, they are not without potential side effects, as immune-related adverse events (irAEs) may occur due to heightened immune activity.

Recent advancements in checkpoint inhibitors include notable industry activities. In February 2025, Genome & Company partnered with Ellipses Pharma for GENA-104, targeting CNTN4. Helix BioPharma Corp. acquired LR 09 from Laevoroc Immunology AG in November 2024. OncoC4, Inc. dosed its first patient in ONC-841-002 trial in August 2024, evaluating ONC-841 for solid tumors. The FDA cleared OncoC4’s IND application for ONC-841 in April 2024, while Mozart Therapeutics began clinical trials for MTX-101 in June 2024.

Company and Product Profiles (Marketed Therapies)

**Bristol Myers Squibb/ Ono Pharmaceuticals**: Bristol Myers Squibb (BMS) is a leader in biopharmaceuticals, emphasizing innovative cancer therapies. Its renowned product, Opdivo, harnesses the body's immune system to combat cancer. Opdivo has significant global approval, showcasing BMS's expertise in immuno-oncology.

**Genentech**: As part of Roche, Genentech pioneered biotech industry advancements. It developed Atezolizumab (Tecentriq), targeting PD-L1 to bolster immune responses against cancer. Approved for multiple cancer types, it exemplifies Genentech's strong R&D focus.

 






Story continues  

Company and Product Profiles (Pipeline Therapies)

**OncoC4**: A clinical-stage enterprise focused on cutting-edge cancer immunotherapies. Their promising product, ONC-841, antagonizes SIGLEC10 to activate immune responses against tumors.

**Kyowa Kirin**: Kyowa Kirin's affiliate, Boundless Bio, explores therapies targeting extrachromosomal DNA, pioneering treatments like BBI-355 for oncogene-amplified tumors, signifying innovation in cancer therapeutics.

**Transcode Therapeutics, Inc**: Focusing on RNA-based cancer therapy, Transcode's TTX-siPDL1 is an RNAi therapeutic reducing PD-L1 expression, enhancing immune system attack on resistant tumors.

Analytical Perspective

The report offers depth on collaborations, licensing, and acquisition trends, elaborating on company interactions and market analysis, vital for understanding the competitive landscape of checkpoint inhibitors. Detailed assessments cover therapeutic and pipeline profiles, unmet needs, and provide vital industry insights.

Key Players include CanBas Co. Ltd, Boundless Bio, OncoC4, and Transcode Therapeutics, with key products like CBP 501, BBI-355, ONC-841, and TTX siPDL1 marking advancements in the field.

Key Topics Covered:

Introduction

Executive Summary

Checkpoint Inhibitors: Overview

Introduction

Classification

Risk factors

Diagnosis

Treatment

Checkpoint Inhibitors - Analytical Perspective: In-depth Commercial Assessment

Checkpoint Inhibitors Collaboration Analysis by Companies

Competitive Landscape

Comparative Assessment of Companies (by therapy, development stage, and technology)

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Checkpoint Inhibitors: Company and Product Profiles (Marketed Therapies)

Bristol Myers Squibb/ Ono Pharmaceuticals

Company Overview

Opdivo

Product Description

Research and Development Activities

Product Developmental Activities

Checkpoint Inhibitors: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Comparative Analysis

Company Name

Company Overview

Drug Name

Product Description

Research and Development Activities

Product Developmental Activities

Mid Stage Products (Phase II)

Comparative Analysis

CanBas Co. Ltd.

Company Overview

CBP 501

Product Description

Research and Development Activities

Product Developmental Activities

Early Stage Products (Phase I)

Comparative Analysis

OncoC4

Company Overview

ONC-841

Product Description

Research and Development Activities

Product Developmental Activities

Preclinical and Discovery Stage Products

Comparative Analysis

Company Name

Company Overview

Product Name

Product Description

Research and Development Activities

Product Developmental Activities

Inactive Products

Comparative Analysis

Checkpoint Inhibitors- Unmet needs

Checkpoint Inhibitors - Market drivers and barriers

Appendix

Companies Featured

CanBas Co. Ltd

Boundless Bio

Sumitomo Pharma America, Inc

Pharos I&BT Co

Virion Therapeutics

OncoC4

Transcode Therapeutics, inc

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Terms and Privacy Policy

Privacy Dashboard

More Info